By Andrew Silver SHANGHAI (Reuters) -Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

A growing number of Americans are trying popular weight-loss drugs touted by celebrities, health care providers and others.

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli Lilly began marketing its rival product Mounjaro in the world's most populous ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy in a mid-stage ...

There's expectations weight-loss drug Wegovy will eventually be funded publicly, according to experts. It's become available ...

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...

Both drugs led to substantial weight loss, but Mounjaro's 20% weight reduction, after 72 weeks of treatment, exceeded the 14% from Wegovy. More in Health A 51-year-old says she's in the best shape ...